Ridgeline Discovery
↗Basel, Switzerland
Ridgeline Discovery is a Versant Ventures Discovery Engine founded in 2017 and headquartered in Basel, Switzerland. It operates as a biotech company creation and development platform with a mission to build leading biotech companies, operate them, help them grow, and establish their independent footprint. Rather than operating as a traditional pharma company, Ridgeline functions as an innovation hub that incubates and nurtures early-stage biotech startups, leveraging partnerships with entrepreneurs, industry leaders, and leading academic institutions across Europe, the US, and globally. The company has assembled an international team of more than 50 highly experienced drug discovery professionals with expertise in medicinal chemistry, DMPK, biology, and proteomics, focused on small molecules, biologics, and gene/cell therapies.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Drug Discovery Platform & Company Creation Engine
SIZE & FINANCIALS
Employees:51-200
Founded:2017
Ownership:subsidiary
Status:operating
FUNDING
Stage:Pre-IPO
Total Raised:$30M
Investors:Versant Ventures
PIPELINE
Stage:Discovery|Preclinical|Phase 1|Phase 2
Lead Drug Stage:Varies by portfolio company
Modalities:Small molecule, mAb, ADC, Degrader-Antibody Conjugates (DACs), Cell therapy, Gene therapy, Bispecific antibodies
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Versant Ventures
Subsidiaries:Black Diamond Therapeutics, Bright Peak Therapeutics, Monte Rosa Therapeutics, Cimeio Therapeutics, Red Ridge Bio, SixPeaks Bio (acquired by AstraZeneca 2025), Firefly Bio
Key Partnerships:ETH Zurich (academic partnerships for drug discovery), Stanford (academic partnerships), Alnylam, DEM BioPharma, Related Sciences, Santa Ana Bio, Solve Therapeutics, Vertex, Adimab, AstraZeneca (SixPeaks Bio collaboration and acquisition), Eli Lilly & Company (Firefly Bio investor), Kyowa Kirin (Cimeio Therapeutics partnership - $300M), Pierre Fabre Laboratories (Red Ridge Bio partnership), New Enterprise Associates (Red Ridge Bio investor)
COMPETITION
Position:Leader
Competitors:Recursion Pharmaceuticals (drug discovery platform), Exscientia (AI drug discovery), Schrödinger (computational chemistry platform), CRO/CDMO companies (for outsourced manufacturing), Traditional big pharma in-house drug discovery, Other Versant Ventures platforms
LEADERSHIP
Key Executives:
Brad Bolzon, Ph.D. - Key Team Member
Alexander Mayweg, Ph.D. - Managing Director
Markus Enzelberger, Ph.D. - EIR (Entrepreneur in Residence) / CSO
Andrew Jefferson - Chief Operating Officer
Florence Widmann - Senior HR Manager
Scientific Founders:Markus Enzelberger, Ph.D. (CSO, protein engineering), Alexander Mayweg, Ph.D. (Managing Director)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Ridgeline Discovery. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.